TG003-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemETG003Cat. No.: HY-15338CAS No.: 719277-26-6分式: CHNOS分量: 249.33作靶點: Others作通路: Others儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 31 mg/mL (124.33 mM)* means soluble, but saturation unkno

2、wn.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 4.0107 mL 20.0537 mL 40.1075 mL5 mM 0.8021 mL 4.0107 mL 8.0215 mL10 mM 0.4011 mL 2.0054 mL 4.0107 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 TG003效的Clk1/Sty抑制劑，抑制Clk1 和Clk4的IC50值分別為20和15 nM。IC50 & Target IC50: 20 nM (Clk

3、1), 200 nM (Clk2), 10 M (Clk3), 15 nM (Clk4) 1體外研究TG003, shows the most potent effect on Clk1/Sty and Clk4 (IC50, 1520 nM) and lesser on Clk2 (200 nM).TG003 inhibits SF2/ASF-dependent splicing of -globin pre-mRNA in vitro by suppression of Clk-mediated1/2 Master of Small Molecules 您邊的抑制劑師www.MedChem

4、Ephosphorylation. It suppresses serine/arginine-rich protein phosphorylation, dissociation of nuclear speckles,and Clk1/Sty-dependent alternative splicing in mammalian cells 1. The small drug TG003 increasesendogenous expression of p53 and p53 protein isoforms by modulation of TP53 intron 9 alternat

5、ivesplicing 2.體內(nèi)研究 Intrathecal injection of either TG003 (1-100 pM) or IC261 (0.1-1 nM) dose-dependently decreasesmechanical allodynia and thermal hyperalgesia induced by carrageenan or CFA 3.PROTOCOLKinase Assay 1 Kinase activity of Clks and SRPKs is assayed in a reaction mixture, containing 200 mM

6、 Tris-HCl (pH 7.5),12.5 mM MgCl2, 8 mM dithiothreitol, 4 mM EGTA, 120 M ATP, 1 Ci of -32PATP, 1 g of syntheticpeptide of SF2/ASF RS domain and 0.1-1 g of purified kinases in a final volume of 40 L. The finalconcentration of Me2SO is adjusted to 1% regardless of inhibitor concentration. The reaction

7、mixture isincubated at 30 or 25 C for mammalian or Xenopus recombinant proteins, respectively, for 10 min, and ahalf-portion is spotted on P81 phosphocellulose membrane. The kinase assay conditions, including theincubation period and concentration of kinases and substrates, are optimized to maintain

8、 the linearity duringincubation. The membrane is washed with 5% phosphoric acid solution or 5% trichloroacetic solution at leastover 15 min. The radioactivity is measured using a liquid scintillation counter 1.MCE has not independently confirmed the accuracy of these methods. They are for reference

9、only.Cell Assay 1 2105 HeLa cells or 1.5105 COS-7 cells re-suspended in 2 mL of medium are plated on 6-well dishes, and2 L of 10 mM TG003 dissolved in Me2SO (final concentration at 10 mM), or 2 L of Me2SO, is added tosome wells. Cells are trypsinized, and the density is counted every 24 h for 3 days

10、. Cells are then fixed with 1mL of ice-cold 70% ethanol, washed with PBS, incubated in 1 mL of PBS containing 1 g/mL DNase-freeRNase A and 50 g/mL propidium iodide for 20 min at 37 C, and proceeded to cell cycle analysis 1.MCE has not independently confirmed the accuracy of these methods. They are f

11、or reference only.戶使本產(chǎn)品發(fā)表的科研獻 Harvard Medical School LINCS LIBRARYSee more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Muraki M, et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem. 2004 Jun 4;279(23):24246-54.2. Marcel V, et al. Modulatio

12、n of p53 and p53 expression by regulating the alternative splicing of TP53 gene modifies cellular response.Cell Death Differ. 2014 Sep;21(9):1377-87.3. Kurihara T, et al. Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different caseinkinase 1 (CK1) inhibitors. Mol Pain. 2014 Mar 10;10:17.McePdfHeight2/2 Master of Small Molecules 您邊的抑制劑師www.MedChemECauti